Structural and virological identification of neutralizing antibody footprint provides insights into therapeutic antibody design against SARS-CoV-2 variants.
Anraku, Y., Kita, S., Onodera, T., Sato, A., Tadokoro, T., Ito, S., Adachi, Y., Kotaki, R., Suzuki, T., Sasaki, J., Shiwa-Sudo, N., Iwata-Yoshikawa, N., Nagata, N., Kobayashi, S., Kazuki, Y., Oshimura, M., Nomura, T., Sasaki, M., Orba, Y., Suzuki, T., Sawa, H., Hashiguchi, T., Fukuhara, H., Takahashi, Y., Maenaka, K.(2025) Commun Biol 8: 483-483
- PubMed: 40121330 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s42003-025-07827-0
- Primary Citation Related Structures: 
8YK4, 8YKG, 8YKH - PubMed Abstract: 
Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation for the severity of COVID-19 patients. We previously reported an antibody, NT-108 with potent neutralizing activity. However, the structural and functional basis for the neutralizing activity of NT-108 has not yet been understood. Here, we demonstrated the therapeutic effects of NT-108 in a hamster model and its protective effects at low doses. Furthermore, we determined the cryo-EM structure of NT-108 in complex with SARS-CoV-2 spike. The single-chain Fv construction of NT-108 improved the cryo-EM maps because of the prevention of preferred orientations induced by Fab orientation. The footprints of NT-108 illuminated how escape mutations such as E484K evade from class 2 antibody recognition without ACE2 affinity attenuation. The functional and structural basis for the potent neutralizing activity of NT-108 provides insights into the rational design of therapeutic antibodies.
- Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Organizational Affiliation: 


